It’s no secret that I love to travel. Upon receiving my idiopathic pulmonary fibrosis (IPF) diagnosis in 2016, my biggest fear was that this cruel lung disease would take away my physical ability to explore the world. While IPF has certainly changed how I travel, I am grateful…
How Planning a Trip Helps Me Cope with PF
The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with idiopathic pulmonary fibrosis (IPF) in South England were found to be similar to real-world data. The research confirmed the safety of both IPF therapies. The retrospective study, “South-West…
All pulmonary fibrosis patients require supplemental oxygen as our disease progresses. As scarring in our lungs worsens, we need extra oxygen to stay alive. Starting using oxygen I was shocked when my doctor told me that I needed to use supplemental oxygen, which involves rolling a tank around…
Synairgen announced it successfully completed three-month toxicity studies on LOXL2 (lysyl oxidase like 2) inhibitor candidates for treating idiopathic pulmonary fibrosis (IPF). The LOXL2 program, developed in collaboration with Pharmaxis, may move into Phase 2 trials. Synairgen and Pharmaxis began their collaboration in 2015 to develop…
There is no question that living with pulmonary fibrosis is exhausting for patients and caregivers alike. Those who may not have any experience with PF might assume that it is only a physically limiting disease. I would have thought the same before my idiopathic pulmonary fibrosis (IPF) diagnosis in…
Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 is a best-in-class autotaxin (ATX) inhibitor, and a potential anti-inflammatory and anti-fibrotic treatment for IPF. Studies have shown…
Blocking the platelet-derived growth factor receptor-beta (PDGFR-β) prevents lung fibrosis in a mice model of pulmonary fibrosis, a study says. Based on these observations, scientists believe that PDGFR-β blockade may someday be a viable therapeutic option for patients with idiopathic pulmonary fibrosis (IPF). The findings of the study, “Blockade…
A new subtype of immune cells carrying a unique genetic profile was identified and found to have an important role in the progression of fibrosis in the lungs, a study reports. The study, “Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage,” was published in…
It’s true what they say about life being unpredictable, and those living with a chronic illness know this better than anyone. Since my diagnosis of idiopathic pulmonary fibrosis (IPF) nearly three years ago, I have faced many uncertain times. And though I’m aware of the fickle nature of…
A small Phase 1 pilot study found improved physical function in idiopathic pulmonary fibrosis (IPF) patients treated with senolytic therapies. The trial was conducted by researchers at University of Texas Health San Antonio, in collaboration with the Mayo Clinic and the Wake Forest School of Medicine. The findings…
